Environmental factors such as stress, anxiety, and epigenetic alterations have been reported to play a significant role in the pathogenesis of sporadic or late-onset AD (LOAD). [7] [8] [9] [10] Epigenetic mechanisms regulate gene expression through histone acetylation and DNA methylation of normal nucleotide sequences of a gene.
There are four families of histone deacetylase (HDAC) enzymes encoded from both the human and rodent genomes: class I (including HDAC 1-3 and 8), class IIa (HDAC 4, 5, 7, and 9), class IIb (HDAC 6 and 10), and class IV (HDAC11). 11 Evidence further suggests that the development of the epigenetic drugs may provide a new direction in AD. 12, 13 Previous experimental treatments with pan-HDAC inhibitors (nonselective HDAC inhibitors, HDACi), such as sodium butyrate, trichostatin A, suberoylanilide hydroxamic acid, or sodium phenylbutyrate, have shown promising therapeutic effects in animal models of AD and neuropsychiatric disorders. [14] [15] [16] However, pan-HDACi should be used with caution because of the unfavorable side effects that they can cause in the brain. 17 Therefore, the development of selective HDACi with the reduction in unwanted side effects needs to be addressed in AD treatments.
In this study, we first identified a lead compound selected from four HDACi that would serve as an appropriate chemical probe to test its therapeutic potential in AD treatment. In mouse primary hippocampal neuronal cultures, we found that MGCD0103 showed neuroprotective effects superior to those of the three other HDACi.
MGCD0103, an isotype-selective HDACi, has been clinically evaluated for the treatment of tumors 18 and has also shown a promising pharmacological profile as an anticancer agent, including reliability, tolerance, and safety. 19, 20 Therefore, the potential therapeutic effects and mechanisms of MGCD0103 were characterized in mice received with an acute bilateral intrahippocampal CA1 injection of oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
Our data show that MGCD0103 can effectively and safely attenuate the anxiety and cognitive deficits associated with an increase in acetylated histone and nonhistone (α-tubulin) proteins and can ameliorate the pathological features of AD, including Aβ deposition, tau protein phosphorylation, gliosis, and loss of serotonergic neurons and synapserelated proteins. Based on these results, we suggest that MGCD0103
could be developed as a novel therapeutic approach for AD.
| ME THODS

| Animals and ethics statement
All experimental procedures using mice received specific approval from the Institutional Animal Care and Use Committee (IACUC) of the National Taiwan Normal University, Taipei, Taiwan (Permit Number: 104010). C57BL/6J mice were purchased from the National Breeding
Centre for Laboratory Animals. In vivo animal experiments were carried out with mature (12-week-old) males, and pregnant females were utilized for primary hippocampal cultures. Mice were maintained on a 12 hours light/dark cycle with a constant ambient temperature (20-25°C) and relative humidity (60%), with food and water available ad libitum. Every effort was made to minimize any suffering to the animals. For in vivo use, Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptides were diluted to 10 nmol/L with physiological saline and aggregated by incubation at 37°C for 7 days before bilateral injection into the hippocampal CA1 subregion (i.c.).
| Preparation of Aβ
The IC50 values of four HDACi (BML210; MGCD0103; PXD101; Droxinostat) were determined by an MTT assay (see Supporting Information) using a SH-SY5Y neuroblastoma cell line (Table S1 ).
HDACi were diluted with DMSO and applied to the primary culture at three different concentrations (Table S1 ; low, medium, and high).
| Administration of MGCD0103
The elimination half-life in plasma of MGCD0103 is 7-11 hours.
22-24
Chronic intrathecal delivery (4 weeks Alzet minipumps) of MGCD0103 (30 or 60 nmol/d) was administrated into the spinal cord of nerve injury rats. 25 In addition, four HDACi (BML210, MGCD0103, PXD101, Droxinostat) in three different doses (high, medium, and low dose based on IC50) were screened using mouse primary hippocampal neuronal culture ( Figure S1 ). We found that the neuroprotective effect of MGCD0103 was superior to the other three HDACi, especially in low and high doses ( Figure S1 ). Furthermore, the performance in neuroprotection of MGCD0103 in high dose was better than low dose ( Figure S2 ). Therefore, the in vivo dose of MGCD0103 (0.5 mg/kg; Biovision) was determined based on the results of the primary hippocampal neuronal cultures (high dose) and evidence of its ability to penetrate the BBB. 23, 24 MGCD0103 was first dissolved in DMSO (40 mg/mL) and then diluted with a mixed buffer (saline:Kolliphor, 4:1; Kolliphor (C5135; Sigma-Aldrich)) to 0.5 mg/kg before intraperitoneal injection (i.p.) in mice once a day for 28 days following stereotaxic surgery. The toxicity of chronic MGCD0103
injections in liver and kidney was assessed by hematoxylin and eosin (HE) staining (Table S2 ).
| Experimental design
Six days after adaption in an animal room, mice were anesthetized on 
| Evaluation of behavioral tasks
During the MGCD0103 treatment period, mice were evaluated in OFT, EPM, Y-maze, and MWM tests. Before the behavioral tests, mice were acclimatized to the behavioral testing room for 30 minutes. All experiments were completed between 7:00 and 17:00, and the behavioral performance of the mice was recorded and analyzed by an automatic tracking system (EthoVision-XT; Noldus, Wageningen, Netherlands). The test box was sequentially cleaned with 70% and 30% ethanol before the next mouse was introduced to the box.
| Open-field test
The OFT was conducted as previously described. 7 Mice were indi- 
| Elevated plus maze
The maze consisted of four arms ( 
| Y-maze
The Y-maze apparatus consisted of 3 identical symmetric arms (46 × 3 × 17 cm) with white acrylic walls. The Y-maze task was conducted as described. 26 Each mouse was placed in the central space and allowed to explore freely for 8 minutes, while their rates of spontaneous alternations were assessed as an indicator of short-term memory. Arm entry was defined as the entry of all four paws into one arm. Spontaneous alternation percentage was calculated by the equation: [successive entries/(total arm entries − 2) × 100].
| Morris water maze
The spatial learning and memory abilities of the mice were assessed through the MWM task as previously described. 7 Before the training phase, the swimming ability of the mice was tested on day 30. Mice that floated in the pool were not enrolled in the task. In the training phase, each mouse underwent four 1-minute trials to locate the hidden platform on 4 consecutive days (days [31] [32] [33] [34] . The time to climb onto the hidden platform was recorded as the escape latency. On day 35, three testing trials were performed as an index of spatial learning acquisition. Twenty-four hours after the last testing trial (day 36), a probe test was performed. The platform was removed from the pool, and each mouse was allowed to swim freely for 60 seconds.
The amount of time spent in the quadrant of the original platform location was calculated as an index of long-term spatial memory.
| Immunohistochemistry (IHC)
Immunohistochemistry staining was performed as previously de- kit (Vector Laboratories, Burlingame, CA, USA). Slices were stained and observed using a light microscope (Leica, Wetzlar, Germany).
Images were obtained using Image-Pro Plus 5.1 (Image-Pro Plus Media Cybernetics, Washington, MD, USA), and the threshold intensity was manually set at a constant value for all images. Pixel counts were derived from the average of three adjacent sections per animal.
| Western blot
Three to five mouse hippocampi from each group were collected and homogenized in RIPA lysis buffer (1:2, w/v). An aliquot of 20 μg protein was used for Western blot analysis as previously described. 7 After blocking, membranes were incubated with the primary antibodies listed in Table 1 at 4°C for 16 hours. Next, membranes were incubated with the secondary antibodies corresponding to the type of primary antibody (1:10 000, Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 2 hours at room temperature and developed using an ECL kit (ECL, Amersham, MA, USA). β-actin was used as a loading control.
Blots were scanned by a LAS-4000 chemiluminescence detection system (Fujifilm, Tokyo, Japan), and the quantification of band density was performed using Gel-Pro Analyzer software (GelPro32, version 4.0; Media Cybernetics, Inc., Rockville, MD, USA).
| Statistical analysis
Data are shown as the mean ± SEM. Data were analyzed by SPSS 20.0 statistics software (Armonk, New York, USA) using one-way ANOVA or Student's t tests. P < 0.05 was considered to be statistically significant. Figure 1C ). These results suggest that the treatment of MGCD0103 ameliorated the anxiety caused by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injections.
In addition, the oligomeric Aβ 25-35 -treated group exhibited significantly reduced short-term memory compared with the saline-treated group in the Y-maze test (P < 0.001; Figure 1D ).
However, the recognition memory performance inhibited by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] was effectively restored by the i.p. administration of MGCD0103 (P < 0.001; Figure 1D ). The treatment with MGCD0103 recovered the short-term memory damage induced by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
In the MWM task, the time for the mice to reach the hidden platform was compared among the four groups ( Figure 1E-H) . First, no significant difference in swimming speeds was found among the four groups of mice ( Figure 1E ). In the 4-day positioning navigation test, the escape latency of the mice was not significantly decreased by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] treatment following training days 1-4 (F 3,59 = 0.68, P > 0.05; Figure 1F ). Compared with the saline-treated group, the group administered Aβ 25-35 had a significant longer escape latency on all 4 days (P < 0.001; Figure 1F ), indicating that the administration of Aβ 25-35 induced a learning deficit. This deficit was ameliorated by the administration of MGCD0103 on days 2-4 (P < 0.05-0.01; Figure 1F ).
On the 5th day of the MWM (testing phase), mice from the Aβ 25-35 -treated group spent more time locating the platform than did saline-treated mice (P < 0.001; Figure 1G ), indicating deficits in memory acquisition. The administration of MGCD0103 significantly improved the memory acquisition damage induced by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (P < 0.05; Figure 1G ). In the saline-treated group,
MGCD0103 treatment significantly impaired memory acquisition
F I G U R E 3 Effects of MGCD0103 on Tau Phosphorylation-Related Proteins in Oligomeric Aβ 25-35 Mice. (A) Representative Western blots and quantitative densitometry results for the ratios of pS9GSK3β/GSK3β (B) and pT205Tau/HT7 (total tau) (C). β-actin was used as an internal control. (D)
Representative immunohistochemical staining of pS202Tau in the CA1 subregion of the hippocampus and the BLA. Scale bar = 100 μm. The arrowheads indicate positive staining of pS202Tau (n = 3-4 per group). Quantitative results for pS202Tau in the CA1 subregion of the hippocampus (E) and the BLA (F). *, compared to the saline (i.c.)/saline (i.p.) group; #, compared to the oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (i.c.)/saline (i.p.) group (*, #, P < 0.05; ##, P < 0.01; ***, ###, P < 0.001) (P < 0.01; Figure 1G ), which suggests that MGCD0103 should not be used before the onset of disease. On the 6th day of the MWM (probe phase), deficits in memory retention were observed in the oligomeric Aβ 25-35 -treated group (P < 0.001; Figure 1H ), and the administration of MGCD0103 improved memory retention (P < 0.001; Figure 1H ).
The results obtained from these different behavioral tasks suggest that the administration of MGCD0103 attenuated the anxiety and cognitive deficits in oligomeric Aβ 25-35 -treated mice.
| MGCD0103 decreased Aβ levels via increasing the expression levels of IDE in oligomeric Aβ 25-35 -treated mice
Immunohistochemistry staining revealed the extensive Aβ deposition in the hippocampus of oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -treated mice compared to saline-treated mice (P < 0.01; Figure 2A,B) . Furthermore, the deposition of Aβ was significantly decreased in the hippocampus of the MGCD0103-treated group under oligomeric Aβ 25-35 conditions (P < 0.01, Figure 2A,B) . In addition, BACE1, IDE, and NEP were also evaluated to elucidate the effects of MGCD0103 on the metabolism of Aβ. The levels of BACE1 in the oligomeric Aβ 25-35 -treated group were significantly higher than those of the salinetreated group (P < 0.01; Figure 2C ,D); however, there was no change following the administration of MGCD0103 (Figure 2C,D) . In addition, MGCD0103 markedly enhanced the reduced expression of IDE induced by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (P < 0.01; Figure 2C ,E). There was no difference in the levels of NEP among the four groups of mice (data not shown). These results indicated that MGCD0103 administration may mitigate Aβ deposition by increasing the levels of IDE.
| MGCD0103 attenuates the increased expression of pTau seen in oligomeric Aβ 25-35 -treated mice
Cyclin-dependent kinase 5 (CDK5) and GSK3β are major kinases that participate in the pathological hyperphosphorylation of tau in both 3xTg-AD mice and the human brain. 27 ,28 Therefore, we used IHC staining and Western blot analyses to evaluate the (inactive form of GSK3β; P < 0.05; Figure 3A ,B) and increased the levels of pTau at the T205 (P < 0.05; Figure 3A ,C) and S202 sites (P < 0.001; Figure 3D ,E) in the hippocampus and the S202 site in the BLA (P < 0.001; Figure 3D ,F) compared to injections of saline. Moreover, the administration of MGCD0103
significantly reversed these changes in pTau-related proteins induced by the Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] oligomer in the hippocampal and BLA regions (P < 0.05-0.001; Figure 3) . However, the levels of CDK5, a second critical tau kinase, were not modulated by MGCD0103 treatment (data not shown). Therefore,
MGCD0103 treatment increased the levels of pS9GSK3β
expression that accompanied the reduction in tau protein phosphorylation at the T205 and S202 sites in oligomeric Aβ 25-35 -treated mice.
| MGCD0103 reduced the gliosis induced by oligomeric Aβ 25-35
Gliosis is a common pathological process in AD 29 ; thus, the modifications in gliosis were evaluated. First, the expression of GFAP (a marker for astrocytes) and Iba1 (a marker for microglia) proteins was measured by IIHC staining. Staining results in the hippocampal region revealed that Aβ 25-35 -inoculated mice had significantly increased levels of GFAP compared to saline-inoculated mice (P < 0.01; Figure 4A ,B). These effects were ameliorated by systemic treatment with MGCD0103
(P < 0.05; Figure 4A ,B). In addition, the number of activated microglia in the hippocampal area showed increased levels of activated microglia in the oligomeric Aβ 25-35 -treated group compared to the levels in the saline-treated group (P < 0.001; Figure 4A ,C); this effect was counteracted by systemic treatment with MGCD0103 (P < 0.001; Figure 4A ,C).
Therefore, we suggest that the administration of MGCD0103 reduced the gliosis that was elevated by the toxicity of oligomeric Aβ 25-35 .
| MGCD0103 ameliorated the loss of serotonergic neurons in oligomeric Aβ 25-35 -treated mice
The progression of cognitive deficits is closely reflected by neuronal loss. 30 The staining results showed that the numbers of noradr- 
| MGCD0103 increased the levels of acetylated histone 3 and α-tubulin and the expression of synaptophysin
In this study, we found that the levels of acetylated H3 at the Lys 9 site (AcH3K9) and α-tubulin were not different in the groups treated with oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 
| D ISCUSS I ON
In the present study, we demonstrated that the systemic chronic ad- to present with the symptoms of dementia. 35 Intrahippocampal injection of oligomeric Aβ via stereotaxic is widely used to generate an animal model for AD study. [36] [37] [38] [39] [40] Evidence also demonstrated that the platform of intrahippocampal Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injection can be used to evaluate the cognitive effects of drug in animals. 38 In addition, it is reported that Aβ 1-40 , the major component of Aβ deposition, which is soluble and nontoxic and is easily converted by brain proteases to truncated toxic fragments, Aβ 25-35/40 . This may account for the lag between Aβ deposition and neurodegeneration in AD. 41 kg once daily) we applied to the mice in this study was much lower than the doses in the treatment of tumors. The dose could be even lowered when it is applied to patients with AD according to the body surface area (BSA) normalization method. 42 In addition, there is no difference in motor activity in the groups of mice with or without the treatment of MGCD0103 during this study. Furthermore, we did not observe significant lesion in pathological examination of livers and kidneys of the sacrificed mice at the end of treatment. These results reveal the low toxicity of MGCD0103 for the AD model.
Psychological symptoms of dementia are an integral part of AD.
43,44
Early evidence shows marked serotonergic neuron loss, predominantly in the raphe nucleus, in patients with AD. 45 Evidence also suggests that a dysregulation of the serotonergic system induces anxiety-like behaviors. 46 Previous immunohistochemical evidence also suggests that serotonergic fibers have dense terminals in the basolateral complex of the amygdala. 47 In addition, HDACi such as valproic acid (VPA) and trichostatin A (TSA) modulate the activity of serotonergic neurons. 48, 49 Growing evidences also suggest that
HDACi ameliorated deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including AD, anxiety, and mood disorders. 16, 50, 51 Furthermore, the serotonergic neurons in the raphe nucleus also innervate the medial prefrontal cortex (mPFC) 52 ; thus, it is reasonable to suggest that the loss of serotonergic neurons in the raphe nucleus can affect cognitive behavior. Evidence also suggests that anxiety traits exacerbate the cognitive impairments and hippocampal vulnerability in patients with AD. 53 Therefore, we suggest that Previous studies also suggest that tau protein phosphorylation at both sites (S202 and T205) not only enhances polymerization but also increases filament formation sensitivity. 57 Therefore, treatment with MGCD0103 may protect the microtubule structure from the damage induced by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] via increasing the levels of α-tubulin acetylation and pS9GSK3β expression and decreasing the levels of phosphorylated tau at the T205 and S202 sites. Next, we further found that MGCD0103 treatment increased only the expression levels of synaptophysin and did not increase those of PSD95. These results are consistent with a previous study that assessed treatment with another HDACi, 4-phenylbutyrate. 54 In this study, oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] increased
Aβ deposition and BACE1 expression and decreased IDE expression. MGCD0103 treatment increased only the levels of IDE, not NEP, under oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] conditions. Furthermore, evidence
shows that the reduction in gliosis was not consistent in HDACi treatment. 58 However, treatment with MGCD0103 attenuated the gliosis induced by oligomeric Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
Taken together, these results reveal MGCD0103 could be a potential therapeutic agent against AD. 
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